Inclusion Criteria:

          -  Patients must have a confirmed diagnosis of non-M3 AML; antecedent myelodysplastic
             syndrome (MDS) is acceptable

          -  Post autologous stem cell transplant bone marrow biopsy core that is consistent with
             morphologic remission

          -  Must have received induction and consolidation chemotherapy, and autologous stem cell
             transplant for AML

          -  Life expectancy of greater than 12 months

          -  Karnofsky performance status 70 or greater

          -  Leukocytes >= 2,000/mcL

          -  Absolute neutrophil count >= 1,000/mcL

          -  Platelets >= 75,000/mcL

          -  Total bilirubin =< 4 X institutional upper limit of normal unless 2nd to Gilbert's
             disease

          -  Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT]) and
             alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 4 X
             institutional upper limit of normal

          -  Creatinine < 1.5 X institutional upper limit of normal OR creatinine clearance >= 30
             mL/min/1.73 m^2 for patients with creatinine levels above institutional normal

          -  Able to take aspirin, or warfarin, or low molecular weight heparin as prophylactic
             anticoagulation

          -  Ability to understand and the willingness to sign a written informed consent document

          -  Must be registered into the mandatory RevAssist® program and be willing and able to
             comply with the requirement of RevAssist®

        Exclusion Criteria:

          -  Patient received chemotherapy or radiotherapy within 2 weeks prior to entering the
             study or has not recovered from adverse events due to agents administered more than 4
             weeks earlier

          -  Patient received another investigational agent after post autologous stem cell
             transplant

          -  Patient who will be receiving another investigational product during the study

          -  Patient who is growth factor or transfusion dependent

          -  Patient has central nervous system leukemia

          -  History of allergic reactions attributed to thalidomide or lenalidomide

          -  History of erythema nodosum, characterized by a desquamating rash while taking
             thalidomide or similar drugs

          -  Prior history of metastatic malignancy

          -  Uncontrolled illness including, but not limited to ongoing or active infection,
             unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations
             that would limit compliance with study requirements; patients must not have suffered
             recent (< 6 months) myocardial infarction, unstable angina, uncontrolled hypertension,
             or difficult to control cardiac arrhythmias

          -  Evidence of uncontrolled congestive heart failure

          -  Active hepatitis B as defined by hepatitis B surface antigen positivity, unless able
             to start dual anti-hepatitis B (HepB) therapy, or already on dual anti-HepB therapy

          -  Patients who are positive for hepatitis B core antibody, but negative for the
             hepatitis B surface antigen, should be on lamivudine 100 mg daily until at least 3
             months post-transplant

          -  Patient is positive for human immunodeficiency virus (HIV) or human T-cell
             lymphotropic virus-1 (HTLV-1)

          -  Women of childbearing potential (defined as a sexually mature woman who has not
             undergone a hysterectomy or who has had menses at any time in the preceding 24
             consecutive months)

          -  Men who did not agree not to father a child and who refused to use a latex condom
             during any sexual contact with women of childbearing potential while taking
             lenalidomide and for 4 weeks after therapy is stopped, even if they have undergone a
             successful vasectomy